Join McGuireWoods for the second webinar in this three-part series,
covering discounts, rebates and value-based pricing models for medical
device and pharmaceutical companies.
In the current enforcement environment, it is unclear whether the Office of
Inspector General of the U.S. Department of Health and Human Services will
issue safe harbors to the federal Anti-Kickback Statute to protect
value-based pricing structures offered by medical device and pharmaceutical
companies. Accordingly, manufacturers should carefully consider the risks
of offering (or continuing to offer) such pricing structures.
In a series of video alerts, McGuireWoods’ healthcare lawyers address
issues providers face and overcoming COVID-19 challenges.
Our programs are intended for the benefit of our clients and contacts and we reserve the right to refuse any registration at our sole discretion.